SelectImmune Pharma holds digital investor meeting

SelectImmune Pharma is offering a digital investors’ meeting via Zoom, on Tuesday December 7th at 12.00 CET, for good dialogue and to follow up from the Annual meeting which was held virtually due to covid-19 restrictions.

We welcome existing owners, other investors and interested parties to join. The meeting participants will be able to hear of the company developments and ask questions. These may be asked online in the meeting or be sent via e-mail to the addresses listed below.

The meeting will be held in Swedish.

Please use this link to participate:

https://us06web.zoom.us/j/88217145556?pwd=cC9naE1FZXBXdW8yTFdISFovdUdyZz09

For written questions, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

Ann Gidner

CEO SelectImmune Pharma AB

Phone: +46 768 17 14 14

E-mail: ann.gidner@selectImmune.com

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are one of the world’s most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.